IL158780A0 - Pharmaceutical combinations comprising a p2t (p2y12) receptor antagonist and another anti-thrombotic agent and their use in the treatment and prevention of thrombosis - Google Patents

Pharmaceutical combinations comprising a p2t (p2y12) receptor antagonist and another anti-thrombotic agent and their use in the treatment and prevention of thrombosis

Info

Publication number
IL158780A0
IL158780A0 IL15878002A IL15878002A IL158780A0 IL 158780 A0 IL158780 A0 IL 158780A0 IL 15878002 A IL15878002 A IL 15878002A IL 15878002 A IL15878002 A IL 15878002A IL 158780 A0 IL158780 A0 IL 158780A0
Authority
IL
Israel
Prior art keywords
thrombosis
prevention
treatment
receptor antagonist
another anti
Prior art date
Application number
IL15878002A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL158780A0 publication Critical patent/IL158780A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL15878002A 2001-05-31 2002-05-29 Pharmaceutical combinations comprising a p2t (p2y12) receptor antagonist and another anti-thrombotic agent and their use in the treatment and prevention of thrombosis IL158780A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101932A SE0101932D0 (sv) 2001-05-31 2001-05-31 Pharmaceutical combinations
PCT/SE2002/001033 WO2002096428A1 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
IL158780A0 true IL158780A0 (en) 2004-05-12

Family

ID=20284321

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15878002A IL158780A0 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations comprising a p2t (p2y12) receptor antagonist and another anti-thrombotic agent and their use in the treatment and prevention of thrombosis

Country Status (24)

Country Link
US (2) US20040146498A1 (xx)
EP (1) EP1397139A1 (xx)
JP (1) JP2004532869A (xx)
KR (1) KR20040003029A (xx)
CN (1) CN100352442C (xx)
AR (1) AR034343A1 (xx)
AU (1) AU2002305952B2 (xx)
BR (1) BR0210034A (xx)
CA (1) CA2447648A1 (xx)
CO (1) CO5550445A2 (xx)
CZ (1) CZ20033246A3 (xx)
EE (1) EE200300589A (xx)
HU (1) HUP0400069A3 (xx)
IL (1) IL158780A0 (xx)
IS (1) IS7051A (xx)
MX (1) MXPA03010761A (xx)
NO (1) NO20035315D0 (xx)
PL (1) PL366510A1 (xx)
RU (1) RU2331422C2 (xx)
SE (1) SE0101932D0 (xx)
SK (1) SK14732003A3 (xx)
TW (1) TWI232751B (xx)
WO (1) WO2002096428A1 (xx)
ZA (1) ZA200308780B (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
JP2004346067A (ja) * 2003-04-28 2004-12-09 Mitsubishi Pharma Corp 抗血栓薬の治療可能時間を延長するための薬剤
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ，インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
ATE469157T1 (de) 2003-10-21 2010-06-15 Inspire Pharmaceuticals Inc Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7504497B2 (en) 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
WO2006045756A1 (en) * 2004-10-25 2006-05-04 Boehringer Ingelheim International Gmbh Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
JP2010508350A (ja) * 2006-10-31 2010-03-18 ヤンセン ファーマシューティカ エヌ．ベー． Ａｄｐｐ２ｙ１２レセプターアンタゴニストとしてのトリアゾロピリミジン誘導体
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
JP5635617B2 (ja) * 2009-11-09 2014-12-03 アレクシオン ファーマシューティカルズ， インコーポレイテッド Ｐｎｈｉｉ型白血球を検出するための試薬および方法、ならびに血栓障害の危険因子としてのそれらの同定
WO2011067571A1 (en) * 2009-12-03 2011-06-09 Astrazeneca Ab Co - crystals of a triazolo [4,5 - d] pyrimidine platelet aggregation inhibitor
EP2515871B1 (en) 2009-12-23 2015-09-23 ratiopharm GmbH Solid pharmaceutical dosage form of ticagrelor
WO2011076401A1 (de) 2009-12-23 2011-06-30 Holger Schankin Acetylsalicylsäure-haltige, im wesentlichen wasserfreie pharmazeutische zusammensetzungen
CN102653539B (zh) * 2011-03-01 2014-09-17 秦引林 一种抗血小板聚集化合物及其药物组合
MX2013014035A (es) * 2011-06-01 2014-01-23 Astrazeneca Ab Nuevo co-cristal ticagrelor.
US20160120869A1 (en) * 2013-05-29 2016-05-05 Ratiopharm Gmbh Solid pharmaceutical dosage form
CN104277039B (zh) * 2014-09-19 2016-06-01 广东东阳光药业有限公司 含有取代丁炔基的吡唑并哌啶酮类化合物及其组合物及用途
WO2016116942A1 (en) * 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
WO2016120729A1 (en) * 2015-01-27 2016-08-04 Astrazeneca Ab Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
CN106204544B (zh) * 2016-06-29 2019-04-05 南京中观软件技术有限公司 一种自动提取图像中标志点位置及轮廓的方法和***

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
EE03616B1 (et) * 1995-07-11 2002-02-15 Astra Pharmaceuticals Limited Uued vereliistakute agregatsiooni pärssivad ained
TWI238827B (en) * 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
KR20020005614A (ko) * 1999-03-11 2002-01-17 블레어 큐. 퍼거슨 Ｘａ 인자 저해제와 아스피린, 조직 플라스미노겐활성화인자(ＴＰＡ), ＧＰⅡｂ／Ⅲａ 길항제, 저분자량헤파린 또는 헤파린의 병용에 의한 혈전증 치료
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations

Also Published As

Publication number Publication date
NO20035315D0 (no) 2003-11-28
BR0210034A (pt) 2004-08-10
EE200300589A (et) 2004-02-16
WO2002096428A1 (en) 2002-12-05
ZA200308780B (en) 2005-02-11
US20040146498A1 (en) 2004-07-29
AR034343A1 (es) 2004-02-18
CZ20033246A3 (cs) 2004-02-18
MXPA03010761A (es) 2004-03-02
TWI232751B (en) 2005-05-21
IS7051A (is) 2003-11-26
CO5550445A2 (es) 2005-08-31
US20060189584A1 (en) 2006-08-24
HUP0400069A3 (en) 2006-02-28
HUP0400069A2 (hu) 2004-04-28
RU2003133216A (ru) 2005-04-20
CN1512885A (zh) 2004-07-14
SE0101932D0 (sv) 2001-05-31
CA2447648A1 (en) 2002-12-05
CN100352442C (zh) 2007-12-05
PL366510A1 (en) 2005-02-07
EP1397139A1 (en) 2004-03-17
RU2331422C2 (ru) 2008-08-20
JP2004532869A (ja) 2004-10-28
AU2002305952B2 (en) 2007-08-09
KR20040003029A (ko) 2004-01-07
SK14732003A3 (sk) 2004-05-04

Similar Documents

Publication Publication Date Title
IL158780A0 (en) Pharmaceutical combinations comprising a p2t (p2y12) receptor antagonist and another anti-thrombotic agent and their use in the treatment and prevention of thrombosis
HK1066466A1 (en) Pharmaceutical formulations of antineoplastic agents in particular temozolomide processes of making and using the same
IL161110A0 (en) Prevention and treatment of restenosis by local admistration of drug
PL359862A1 (en) Benzophenones as inhibitors of il-1beta and tnf-alpha
IL211288A0 (en) Vaginally administered anti-dysrhythmic agents for treating pelvic pain and infertility
HUP0400248A3 (en) Mch antagonists pharmaceutical compositions containing them and their use in the treatment of obesity
GB0111872D0 (en) Therapeutic agents and methods
HUP0303927A3 (en) Combination therapy using anti-angiogenic agents and tnf-alpha
IL149495A0 (en) Pharmaceutical formulations comprising p2t receptor antagonist and anti-thrombotic agent and use thereof in therapy
EP1350431A4 (en) METHOD FOR SELECTING AN ANTIMICROBIAL AGENT AND METHOD OF USING THE SAME
GB0108470D0 (en) Pharmaceutical compositions and their use
GB0105613D0 (en) Pharmaceutically effective compounds and their use
IL156506A0 (en) Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
GB0119025D0 (en) Compounds and their therapeutic use
HUP0303612A3 (en) Bicyclic guanidine derivatives and their therapeutic use
EP1371371A4 (en) USE OF N-ACETYL-D-GLUCOSAMINE IN THE PRODUCTION OF A PHARMACEUTICAL AGENT FOR THE PREVENTION AND TREATMENT OF SEXUAL DISORDERS
GB0119370D0 (en) Therapeutic agent
EP1557169A4 (en) THERAPEUTIC AND / OR PROPHYLACTIC AGENT FOR DYSCHEZIA
EP1392460A4 (en) AMINOSILANOL HYDROFLUORIDES AND THEIR USE
GB2376943B (en) Compounds and their therapeutic use
GB0112237D0 (en) Compounds and their therapeutic use
HUP0401041A3 (en) Use an inhibitor of the renin-angiotensin system for the treatment of lipodystrophy the preparation pharmaceutical composition using in
IL152931A0 (en) BENZOPHENONES AS INHIBITORS OF IL-1beta AND TNF-alpha
GB0125210D0 (en) Therapeutic agent
GB0108589D0 (en) Therapeutic agent